Wirkstoffe & Arzneimittelsicherheit

Nebenwirkungen · Plegridy

Plegridy 63 micrograms solution for injection in pre-filled syringe Plegridy 94 micrograms solution for injection in pre-filled syringe Plegridy 125 micrograms solution for injection in pre-filled syringe Plegridy 63 micrograms solution for injection in pre-filled pen Plegridy 94 micrograms solution for injection in pre-filled pen Plegridy 125 micrograms solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 11

HOS-130123 · Präparat HOS-096849

Paediatric population The safety of peginterferon beta-1a in paediatric patients aged 10 to less than 18 years was studied in an open-label randomized active controlled paediatric trial with 152 paediatric patients with RRMS (peginterferon beta-1a n=75; interferon beta-1a n=77). Fifty-eight paediatric patients in the peginterferon beta-1a group completed 96 weeks of this study. The following adverse events which are very common in the adult population were also reported as very common in the paediatric population: injection site erythema, influenza like illness, headache and pyrexia. The adverse event alanine aminotransferase increased was very commonly reported (in adults commonly reported).

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.